阿替利珠单抗联合贝伐珠单抗治疗肝细胞癌的现况  

Current Status of Atezolizumab Combined with Bevacizumab in the Treatment of HepatocellularCarcinoma

作　　者：田维松 余天雾[1] 

机构地区：[1]重庆医科大学附属永川医院肝胆外科,重庆

出　　处：《临床医学进展》2024年第12期296-300,共5页Advances in Clinical Medicine

摘　　要：肝细胞癌(简称肝癌)是高发的恶性肿瘤,据国家癌症中心报告,截至2022年,在所有恶性肿瘤的发病率中,肝癌发病率位居第四。中国虽为乙肝大国,但我国肝癌的早期诊断率低,仅有不到30%的患者具备根治性手术的机会,大多数肝癌患者在初诊时已属中晚期(中国肝癌分期IIb期、IIIa期、IIIb期)。针对中晚期肝癌,系统抗肿瘤治疗是重要的治疗手段。近年来随着免疫检查点抑制剂联合靶向药物的应用,肝癌患者的总生存期得到显著提高,其中代表药物阿替利珠单抗(atezolizumab, A) + 贝伐珠单抗(bevacizumab, T)治疗方案(A + T方案)已被国内外多个指南推荐作为既往未接受过系统治疗的不可切除肝癌的一线治疗方案。本文将对A + T方案治疗肝癌的现况进行阐述。Hepatocellular carcinoma (liver cancer) is a high incidence of malignant tumors, with the fourth highest incidence of liver cancer as of 2022, according to the National Cancer Center. Although China is a big country with hepatitis B, the early diagnosis rate of liver cancer in China is low, and only less than 30% of the patients have the opportunity of radical surgery. Most of the liver cancer patients with initial diagnosis are in the middle and advanced stage (China liver cancer staging IIb, IIIa and IIIb). Systematic anti-tumor therapy is an important treatment method for middle and advanced liver cancer. In recent years, with the application of immune checkpoint inhibitors combined targeted drugs, the overall survival of liver cancer patients was significantly improved, the representative drug atezolizumab + bevacizumab treatment (A + T regimen) has been recommended multiple guidelines at home and abroad as previously not received systemic treatment of unresectable liver cancer. This paper will describe the current status of A + T regimen.

关 键 词：肝细胞癌 阿替利珠单抗 贝伐珠单抗 

分 类 号：R73[医药卫生—肿瘤]